Intuitive Surgical, Inc. research snapshot
ISRG AI stock analysis currently reads Intuitive Surgical as a high-quality robotic surgery platform company with strong procedure growth, a large installed base, high recurring instruments and accessories revenue, and a debt-free balance sheet. At the July 8, 2026 data cutoff, ISRG traded near $427.30 with a verified market capitalization of about $151.33 billion. The main offset is valuation: the stock still prices in durable growth even after its pullback from the 52-week high. This page uses scenario ranges, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$427.30
Market cap
$151.33 billion
AI score
79 / 100
Rating
High-quality robotic surgery leader with premium valuation and procedure-growth sensitivity
Trend status
Recovering near the 50-day moving average, still below the 200-day moving average
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Intuitive sells and leases robotic surgery systems, then earns recurring instruments, accessories, and service revenue as procedure volume grows across da Vinci and Ion platforms. | High |
| Moat | The moat comes from installed systems, surgeon training, procedure data, hospital workflow integration, clinical evidence, regulatory clearances, service infrastructure, and a large instrument ecosystem. | High |
| Management | CEO Dave Rosa has deep company tenure and engineering roots. Capital allocation remains focused on product development, manufacturing capacity, direct distribution expansion, and buybacks. | Medium-high |
| Financial trend | FY2025 revenue was about $10.065 billion and FY2025 net income attributable to common shareholders was about $2.856 billion. Q1 2026 revenue rose 23% to $2.771 billion. | High |
| Valuation | At $427.30, ISRG traded near 51.79x TTM EPS, 8.84x book value, and 54.50x free cash flow per share, so the market still expects long-duration growth. | High |
| Technical trend | The stock was almost exactly at its 50-day moving average near $427.69 and below its 200-day moving average near $488.42, which makes the short-term bounce fragile until longer trend resistance is reclaimed. | Medium |
| Risk level | Key risks are premium valuation, hospital budget cycles, tariff and supply-chain costs, regulatory scrutiny, competition from Medtronic, Johnson & Johnson, CMR Surgical and others, and slower bariatric or OUS growth. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact return outcomes because the multiple can move sharply if procedure growth or gross margin expectations change. | High data confidence |
| Investment certainty | Medium certainty. ISRG is a rare medical technology compounder, but margin of safety depends on whether da Vinci 5, Ion, and international adoption can keep compounding above market expectations. | Medium |
ISRG AI stock forecast
The ISRG AI stock forecast uses scenario math around the $427.30 quote and TTM diluted EPS of $8.25. The audited three-year framework produced a bearish area near $295, a base area near $464, and a bullish area near $618 before any incremental buyback effect. The range is wide because ISRG combines durable procedure growth with a premium earnings multiple.
$590 to $640
More likely if EPS compounds near 16% annually, worldwide da Vinci procedures stay in the mid-teens, da Vinci 5 placements keep rising, Ion procedures grow from a larger base, tariffs are absorbed, and the market values ISRG near 48x earnings.
$440 to $490
More likely if EPS compounds near 12% annually, 2026 procedure growth lands inside management guidance, non-GAAP gross margin stays near the guided range, system leasing remains healthy, and investors value ISRG around 40x earnings.
$275 to $315
More likely if procedure growth slows, hospital capital budgets tighten, China or Japan remains soft, bariatric pressure worsens, tariffs hurt margins, competitive robotic platforms gain traction, and the market compresses ISRG toward 30x earnings.
ISRG AI technical analysis
ISRG AI technical analysis is mixed as of the July 8, 2026 cutoff. The stock had rebounded from recent weakness but sat near the 50-day moving average and remained below the 200-day moving average. RSI near 56 was neutral to modestly positive. Technical levels should be refreshed with live chart data before trading.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $427.30 | July 7, 2026 close used for market cap and valuation math at the July 8 data cutoff. |
| Near support | $411 to $428 | The 20-day and 50-day moving average zone is the first support band after the rebound. |
| Deeper support | $397 to $405 | The lower recent trading range and 52-week low area are the next downside references if the bounce fails. |
| Near resistance | $453 to $488 | The 100-day and 200-day moving averages are the main overhead tests for trend repair. |
| 50-day moving average | About $427.69 | Price was nearly flat with this intermediate trend gauge, so confirmation still matters. |
| 200-day moving average | About $488.42 | Price was still below this long-term trend gauge, which keeps the broader chart in recovery mode rather than confirmed uptrend mode. |
| Momentum | RSI about 56.11 | Momentum was neutral to modestly positive and not overbought by itself. |
| Volume | About 2.56 million average daily shares over 20 days | A breakout above the 100-day or 200-day moving average should be judged against recent average volume. |
| Volatility | Beta about 1.46 | The stock has traded with higher-than-market volatility, so earnings and guidance events can move position risk quickly. |
| Invalidation | Close below $411, then $397 | A close below the 20-day moving average would weaken the rebound. A break below the recent low area would signal a failed setup. |
ISRG AI trading strategy
The ISRG AI trading strategy is a rules-based framework for a high-quality medical technology compounder trading at a premium multiple. It is not personal advice and should be paired with live quotes, filings, position sizing, and risk controls.
Watch for ISRG to hold the $411 to $428 support band and then reclaim the 100-day moving average near $453 and 200-day moving average near $488 with volume confirmation and stable procedure-growth commentary.
A close below about $411 or a failed move at the 100-day moving average should invalidate the short-term setup.
If ISRG pulls back toward the high $300s without a new product, regulatory, margin, or procedure-growth shock, compare the price with the three-scenario valuation range, Q1 momentum, and 2026 guidance.
Do not average down without a defined loss limit because high-multiple medtech compounders can keep derating when expected growth slows.
Track worldwide da Vinci procedure growth, da Vinci 5 placements, Ion procedure growth, instruments and accessories revenue, systems leasing mix, installed base growth, non-GAAP gross margin, tariffs, buybacks, and competitive launches.
Reduce confidence if EPS growth relies mainly on tax benefits, buybacks, or multiple expansion instead of procedure volume, installed-base growth, platform adoption, and operating leverage.
Investment research summary
Intuitive helps surgeons and hospitals perform minimally invasive procedures with robotic systems. Customers pay for systems, instruments, accessories, service, training, and workflow support because the platform can expand procedure capability and standardize care teams around da Vinci and Ion.
The moat is strongest where installed systems, trained surgeons, hospital workflows, service support, regulatory approvals, and clinical evidence reinforce each other. New platforms can compete, but displacing a trained surgical ecosystem is harder than selling a standalone device.
The thesis fails if procedure growth slows, hospitals delay capital spending, new competitors narrow performance gaps, tariffs or manufacturing costs pressure margins, regulators tighten approvals, or the stock keeps a premium multiple while growth normalizes.
Dave Rosa has long Intuitive tenure and frames the business around patient outcomes, care-team experience, cost to treat, and access. The key capital allocation test is whether heavy R&D, manufacturing expansion, distribution changes, and buybacks produce durable per-share value.
Robotic-assisted minimally invasive surgery sits inside a long health-care automation trend. Aging populations, surgeon shortages, data-driven training, and hospital demand for repeatable procedures support adoption, but reimbursement and hospital budgets can slow the pace.
ISRG is priced like a category leader. The margin of safety is not balance-sheet survival because net cash is strong. It depends on whether recurring instruments and accessories revenue, da Vinci 5, Ion, and international adoption can justify a valuation above 50x trailing earnings.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ISRG price | $427.30 close on July 7, 2026 | StockAnalysis market data snapshot | July 8, 2026 |
| Market capitalization | $151.33 billion, verified as $427.30 x 354.16 million shares with 0.00% variance | financial_rigor.py market cap verification | July 8, 2026 |
| Shares outstanding | 354.16 million shares | StockAnalysis statistics | July 8, 2026 |
| FY2025 revenue | $10.065 billion, cross-validated against Intuitive 2025 Form 10-K and StockAnalysis | Intuitive 2025 Form 10-K and StockAnalysis financials | July 8, 2026 |
| FY2025 net income attributable to common shareholders | $2.856 billion, cross-validated against Intuitive 2025 Form 10-K and StockAnalysis net income to common | Intuitive 2025 Form 10-K and StockAnalysis financials | July 8, 2026 |
| Q1 2026 revenue | $2.771 billion, up 23% year over year | Intuitive Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 cash, cash equivalents, and investments | $7.979 billion, cross-validated against Intuitive Q1 2026 release and StockAnalysis balance sheet | Intuitive Q1 2026 earnings release and StockAnalysis balance sheet | July 8, 2026 |
| Q1 2026 installed base | 11,395 da Vinci systems and 1,041 Ion systems as of March 31, 2026 | Intuitive Q1 2026 earnings release | July 8, 2026 |
| Procedure growth | Q1 2026 worldwide da Vinci and Ion procedures grew about 17% year over year | Intuitive Q1 2026 earnings release | July 8, 2026 |
| Valuation ratios | 51.79x TTM PE, 8.84x PB, 54.50x P/FCF, and 1.83% FCF yield from financial_rigor.py | financial_rigor.py valuation verification | July 8, 2026 |
| Technical snapshot | 50-day MA $427.69, 200-day MA $488.42, RSI 56.11, 20-day average volume about 2.56 million | StockAnalysis statistics and Barchart technical analysis | July 8, 2026 |
| 2026 outlook | Management guided to about 13.5% to 15.5% worldwide da Vinci procedure growth and 67.5% to 68.5% non-GAAP gross margin | Intuitive Q1 2026 earnings release | July 8, 2026 |
This ISRG AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available data as of July 8, 2026 and may be wrong if filings, prices, procedure growth, margins, competition, regulation, or market conditions change.
